Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Aliya Pharmaceuticals Inc. focuses its patent efforts in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action under review. This prosecution is being handled by 1 distinct examiner and is located within 1 distinct art unit, indicating a concentrated effort on a specific pharmaceutical technology.
KWON, JOHN SEUNGJAI is the busiest examiner for the portfolio, managing the 1 pending office action. Since there is only 1 pending office action for the entire company, this examiner is the primary authority for the company's current patent applications. The outcome of this single prosecution will be a significant indicator for the company's intellectual property status in this sector.
The involvement of 1 distinct art unit allows for a streamlined prosecution strategy. Practitioners can focus on the specific rules and trends of that unit without the need to manage multiple examiners. With 1 distinct examiner and 1 pending office action, the company's current interaction with the patent office is highly focused and direct.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KWON, JOHN SEUNGJAI | 1 | 45.7% | +19.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18004601 | ANTI-CANCER ACTIVITY OF PERBORATE SALTS | KWON, JOHN SEUNGJAI | 47d |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18004601 | ANTI-CANCER ACTIVITY OF PERBORATE SALTS | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | 47d | Pending | Jan 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial